menu
    • menu
    [{"orgOrder":0,"company":"CareDx","sponsor":"TC BioPharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"OmnImmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ TC BioPharm","highestDevelopmentStatusID":"8","companyTruncated":"CareDx \/ TC BioPharm"},{"orgOrder":0,"company":"CareDx","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CareDx \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"CareDx","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"VIR-7831","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CareDx \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CareDx \/ Vir Biotechnology"}]

    Find Clinical Drug Pipeline Developments & Deals by CareDx

    Menu

    CareDx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CareDx

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OmnImmune

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : TC BioPharm

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CareDx, TC BioPharm Partner on AlloCell Monitoring for Cell Therapy Trial

                            Details : The partnership aims to support ACHIEVE clinical trial using AlloCell to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma-delta T-cell therapy for patients with AML or MDS.

                            Product Name : TCB008

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : OmnImmune

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : TC BioPharm

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CareDx

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegoprubart

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Eledon Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement

                            Details : Collaboration agreement provides Eledon with access to CareDx’s best-in-class technologies, including the study to evaluate the safety, efficacy and pharmacokinetics of AT-1501 in de novo kidney transplant recipients.

                            Product Name : AT-1501

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 19, 2021

                            Lead Product(s) : Tegoprubart

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Eledon Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CareDx

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            CareDx

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIR-7831

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Vir Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CareDx Supports Vir Biotechnology’s Clinical Trial Recruitment Efforts for COMET-ICE

                            Details : The ongoing trial is evaluating VIR-7831, a fully human anti-SARS-CoV-2 monoclonal antibody, for the early treatment of COVID-19 in adults at high risk of hospitalization.

                            Product Name : VIR-7831

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 23, 2021

                            Lead Product(s) : VIR-7831

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Vir Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth